RTX-240 is an investigational cellular therapy that aims to activate the immune system to fight cancer.
RTX-240 is an engineered red blood cell that is being evaluated in a Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.
RTX-240 is an investigational cellular therapy that is designed to activate and amplify the effects of immune system cells called natural killer (NK) cells and T cells, which play a role in killing tumor cells. The Phase 1/2 clinical study of RTX-240 has two arms – one in all solid tumors and one in relapsed AML or refractory AML
Learn more about RTX-240